Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
For more information about Entrada, please visit our website, , and follow us on LinkedIn.BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET).
波士頓，2024年12月18日（環球新聞）-- Entrada Therapeutics, Inc.（納斯達克：TRDA）是一家臨床階段的生物製藥公司，旨在通過建立一種新的藥物類別來改變患者的生活，這些藥物針對長期被認爲無法接觸的細胞內靶點。公司今天宣佈，首席執行官Dipal Doshi將在2025年1月15日（星期三）太平洋時間上午11:15（東部時間下午2:15）在第43屆J.P.摩根醫療保健大會上進行演講。
A live webcast will be available on the Presentations portion of Entrada's Investor Relations website at . The webcast will be archived and available for replay for 30 days after the event.
在Entrada的投資者關係網站的演示部分將提供直播網絡廣播。 該網絡廣播將在活動結束後保存並可重播30天。
About Entrada Therapeutics
Entrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, ocular, metabolic and immunological diseases, among others. The Company's lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45 and 50 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
關於Entrada Therapeutics
Entrada Therapeutics是一家臨床階段的生物製藥公司，旨在通過建立一種新的藥物類別來改變患者的生活，這些藥物針對長期被認爲無法接觸的細胞內靶點。公司的內吞逃逸載體（EEV）療法旨在有效地將多種治療藥物輸送到各種器官和組織中，從而提高治療指數。通過這一專有的、多功能的模塊化方法，Entrada正在推進一項強大的發展組合，包含基於RNA、抗體和酶的項目，潛在用於治療神經肌肉、眼科、代謝和免疫疾病等。公司的主要寡核苷酸項目正在開發，針對能夠進行44、45和50外顯子跳躍的杜氏肌營養不良症患者。Entrada已經合作開發了一個臨床階段的項目VX-670，用於1型強直性肌營養不良。
For more information about Entrada, please visit our website, , and follow us on LinkedIn.
欲了解有關Entrada的更多信息，請訪問我們的網站， , 請關注我們 LinkedIn.
Investor and Media Contact
Caileigh Dougherty
Head of Investor Relations & Corporate Communications
cdougherty@entradatx.com
投資者和媒體聯繫方式
Caileigh Dougherty
投資者關係和公司溝通主管
cdougherty@entradatx.com
譯文內容由第三人軟體翻譯。
